Our predictive patient monitoring software allows healthcare providers to respond to life-threatening medical events before they occur.
Using cutting-edge machine learning techniques employed at CERN's Large Hadron Collider, we identify subtle changes preceding patient deterioration that are invisible to both physicians and standard patient monitoring software, transforming the patient monitoring paradigm from reactive to predictive.
Our first patented technology—built using the largest database of its kind—identifies patients at imminent risk of sudden cardiac arrest, allowing doctors and nurses to take preventive actions.
The American Heart Association recommends early intervention as the centerpiece of its guidelines on improving cardiac arrest care, based on research showing that early action saves lives and improves neurological outcomes among survivors. Our technology offers new hope for the 299,000 patients who experience cardiac arrest in US hospitals each year—of whom only 25% survive—and for the 6 million people around the world who die from sudden cardiac arrest annually.
With funding from leading mission-driven organizations (Wellcome Trust, Innovate UK, EU Data Pitch, Enterprise Estonia, Prototron) and investors (Tera Ventures, InHealth Ventures, Entrepreneur First, AI Seed), we are bringing our sudden cardiac arrest prediction technology to patients and developing our next generation of predictive technologies.
The future is already here -
it's just not evenly distributed.
- William Gibson
We'd like to hear from you! Contact us here.
Transformative AI OÜ has been granted aid of €421,476 euros from Enterprise Product Development Support, Enterprise Development Program and Applied Research Program (2014-2020.15.3.2). Transformative is developing CodeRhythm, a machine learning algorithm that analyses continuous cardiac data to predict shockable cardiac arrest, helping doctors take preventive actions and improve survival. The aim of the proposed applied research project is to carry out development activities for CodeRhythm to be validated in laboratory environment (TRL 5), together with North Estonia Medical Centre, a leading hospital in acute cardiac care. The project is funded as part of the Union's response to the COVID-19 pandemic from European Regional Development Fund.